| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAGEB1 |
| Uniprot No | P43366 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-347aa |
| 氨基酸序列 | MPRGQKSKLRAREKRRKAREETQGLKVAHATAAEKEECPSSSPVLGDTPTSSPAAGIPQKPQGAPPTTTAAAAVSCTESDEGAKCQGEENASFSQATTSTESSVKDPVAWEAGMLMHFILRKYKMREPIMKADMLKVVDEKYKDHFTEILNGASRRLELVFGLDLKEDNPSGHTYTLVSKLNLTNDGNLSNDWDFPRNGLLMPLLGVIFLKGNSATEEEIWKFMNVLGAYDGEEHLIYGEPRKFITQDLVQEKYLKYEQVPNSDPPRYQFLWGPRAYAETTKMKVLEFLAKMNGATPRDFPSHYEEALRDEEERAQVRSSVRARRRTTATTFRARSRAPFSRSSHPM |
| 预测分子量 | 46.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MAGEB1重组蛋白的模拟参考文献示例(注：内容为假设性概括，实际文献需通过学术数据库检索确认)：
---
1. **文献名称**: *"Recombinant MAGEB1 Protein Expression and Its Role in Tumorigenesis"*
**作者**: Wang et al.
**摘要**: 研究利用大肠杆菌系统成功表达并纯化重组MAGEB1蛋白，通过体外实验验证其促进肿瘤细胞增殖的能力，并发现其通过激活MAPK信号通路影响癌症进展。
2. **文献名称**: *"Structural and Immunogenic Characterization of MAGEB1 Recombinant Protein for Cancer Vaccine Development"*
**作者**: Kim et al.
**摘要**: 通过杆状病毒-昆虫细胞系统表达重组MAGEB1蛋白，解析其晶体结构，并证明其在动物模型中诱导特异性T细胞免疫应答，提示其作为肿瘤疫苗抗原的潜力。
3. **文献名称**: *"MAGEB1 Recombinant Protein Interacts with RING1 Protein to Modulate Epigenetic Regulation"*
**作者**: García-Sánchez et al.
**摘要**: 研究重组MAGEB1蛋白与Polycomb复合物成员RING1的相互作用，揭示其可能通过表观遗传调控参与胚胎发育及肿瘤发生。
4. **文献名称**: *"High-Yield Production of MAGEB1 Recombinant Protein in Mammalian Cells for Diagnostic Assay Development"*
**作者**: Li et al.
**摘要**: 优化哺乳动物细胞表达系统(如HEK293)实现重组MAGEB1蛋白的高效分泌表达，并基于此开发ELISA检测试剂盒，用于癌症患者血清中MAGEB1抗体的筛查。
---
建议通过PubMed、Web of Science或Google Scholar等平台，以关键词“MAGEB1 recombinant protein”、“MAGEB1 expression”或“MAGEB1 function”检索最新文献以获取准确信息。
MAGEB1 (Melanoma-Associated Antigen B1) is a member of the MAGE gene family, which encodes cancer-testis antigens (CTAs) predominantly expressed in germ cells and aberrantly activated in various cancers. Located on the X chromosome, MAGEB1 contains a conserved MAGE homology domain (MHD) involved in protein-protein interactions. Like other MAGE family members, MAGEB1 is normally silenced in somatic tissues due to promoter hypermethylation but is reactivated in malignancies, including melanoma, lung, breast, and hepatocellular carcinomas. This tumor-specific expression pattern makes it a potential target for immunotherapy and biomarker development.
Functionally, MAGEB1 is implicated in transcriptional regulation, cell cycle progression, and apoptosis evasion. It interacts with E3 ubiquitin ligases (e.g., RING1B) to modulate ubiquitination pathways, potentially stabilizing oncoproteins or degrading tumor suppressors. Its role in promoting cell proliferation and survival has been linked to cancer progression and therapy resistance. However, its exact molecular mechanisms remain partially characterized, partly due to functional redundancy within the MAGE family.
Recombinant MAGEB1 protein is produced using heterologous expression systems (e.g., E. coli or mammalian cells) for research and therapeutic applications. Purification typically involves affinity tags (e.g., His-tag) followed by chromatography. The recombinant protein is utilized to study MAGEB1's biochemical interactions, develop cancer vaccines, or generate antibodies for diagnostic assays. In immunotherapy, MAGEB1-derived peptides are explored as targets for T-cell-based therapies, such as CAR-T or checkpoint inhibitors, though challenges like antigen heterogeneity and immune evasion persist.
Current research focuses on elucidating its oncogenic pathways, improving antigen presentation, and minimizing off-target effects. MAGEB1's restricted normal tissue expression and immunogenicity position it as a promising candidate for precision oncology, particularly in cancers with limited treatment options.
×
